MBI extends Mallinckrodt's FS069 rights
Molecular Biosystems of San Diego has extended Mallinckrodt Medical'srights to its FS069 ultrasound contrast agent to Europe, Russia,Africa, and India. In exchange for the new rights, Mallinckrodtof St. Louis will pay MBI fees of up to $12.9 million,
Molecular Biosystems of San Diego has extended Mallinckrodt Medical's
rights to its FS069 ultrasound contrast agent to Europe, Russia,
Africa, and India. In exchange for the new rights, Mallinckrodt
of St. Louis will pay MBI fees of up to $12.9 million, plus 40%
of product sales for royalties and manufacturing. The companies
filed a premarket approval application for U.S. marketing of FS069,
a second-generation contrast agent, earlier this year. They plan
to file for European approval in early 1997.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
